


REMARKS

In response to the restriction requirement dated April 3, 2008, Applicants hereby elect the invention of Group (I), represented by Claims 1-3, 6 and 7, drawn to “a method for improving or treating impairments in perception, concentration, cognitive processes, learning and/or memory” with a selective PDE9A inhibitor.

As a species for a mental process Applicants hereby elect “cognitive processes”.

As a species for a PDE9A inhibitor Applicants hereby elect the compound of Formula (I) as set forth in Claims 6 and 7 and depicted below.



The election is made without traverse.

Accordingly, Applicants respectfully submit that this application is now in condition for early examination. If any points remain at issue which can best be resolved by way of telephonic or personal interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

Respectfully submitted,

/Edouard G. Lebel/
Edouard G. Lebel, Ph.D.
Agent for Applicants
Reg. No. 43,742

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 778-7635
Fax: (203) 798-4408
Dated: July 30, 2008